Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gamolenic acid - Scotia Pharmaceuticals

Drug Profile

Gamolenic acid - Scotia Pharmaceuticals

Alternative Names: Efamast; Efarmol; Epogam; Epogam Snip-Off capsules; Epostart; Gamma linolenic acid; Gamolenic acid/vitamin E; Primast; Primogam

Latest Information Update: 03 Oct 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scotia Holdings [CEASED]; Scotia Pharmaceuticals [CEASED]
  • Class Small molecules; Unsaturated fatty acids
  • Mechanism of Action Cell adhesion molecule inhibitors; Immunomodulators; Prostaglandin synthase stimulants; Thromboxane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis
  • Market Withdrawal Breast pain
  • Discontinued Breast cancer; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top